Travere Therapeutics, Inc. (TVTX)
| Market Cap | 1.56B |
| Revenue (ttm) | 194.03M |
| Net Income (ttm) | -78.07M |
| Shares Out | 50.93M |
| EPS (ttm) | -1.70 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 1 |
| Last Price | $30.56 |
| Previous Close | $30.82 |
| Change ($) | -0.26 |
| Change (%) | -0.84% |
| Day's Open | 31.34 |
| Day's Range | 29.95 - 31.60 |
| Day's Volume | 420,365 |
| 52-Week Range | 8.98 - 33.09 |
Travere (TVTX) delivered earnings and revenue surprises of -451.16% and -0.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Travere Therapeutics (NASDAQ:TVTX) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 31.43% over the past year to ($0.4...
Recently reported that ongoing DUPLEX Study of sparsentan in FSGS achieved interim proteinuria endpoint
Travere Therapeutics (NASDAQ:TVTX) unveils its next round of earnings this Monday, March 01. Get prepared with Benzinga's ultimate preview for Travere Therapeutics's Q4 earnings.
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferenc...
Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Travere Therapeutics (TVTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the European Commission (EC) has granted orphan designation to sparsentan for the treatme...
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the completion of its previously announced underwritten public offering of 7,532,500 shar...
SAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2020 financial results on Monday, March 1, 20...
SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 6,550,000 shares of its common stock at...
SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to mark...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that their ongoing pivotal Phase 3 DUPLEX Study...
Travere Therapeutics Inc (NASDAQ: TVTX) share gains after announcing positive interim results from the ongoing Phase 3 DUPLEX study evaluating sparsentan in focal segmental glomerulosclerosis ...
Sparsentan achieved statistically significant response on interim proteinuria endpoint compared to irbesartan after 36-weeks of treatment
SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to s...
Pipeline of potential first-in-class therapies on track to deliver two pivotal readouts in 2021 Pipeline of potential first-in-class therapies on track to deliver two pivotal readouts in 2021
Investors need to pay close attention to Travere Therapeutics (TVTX) stock based on the movements in the options market lately.
Topline data from interim 36-week proteinuria endpoint on track for first quarter of 2021 Topline data from interim 36-week proteinuria endpoint on track for first quarter of 2021
Addition of OT-58 strengthens pipeline of potential first-in-class therapies targeting rare diseases Addition of OT-58 strengthens pipeline of potential first-in-class therapies targeting rare...
SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming virtual investor conferences in Novem...
Retrophin's (RTRX) CEO Eric Dube on Q3 2020 Results - Earnings Call Transcript
Retrophin (RTRX) delivered earnings and revenue surprises of 25.42% and 6.47%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Pivotal DUPLEX Study of sparsentan in FSGS nears completion of enrollment; topline proteinuria data expected 1Q21
Retrophin (RTRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agreement a dd s OT-58, a novel enzyme replacement therapy in Phase 1/2 development for the treatment of classical homocystinuria
SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2020 financial results on Thursday, November 5, 2020 after the close of...
SAN DIEGO, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that on October 10, 2020, the Compensation Committee of its Board of Directors granted inducement eq...
SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with foc...
Topline data from 36-week proteinuria endpoint anticipated in third quarter of 2021 Topline data from 36-week proteinuria endpoint anticipated in third quarter of 2021
Retrophin, Inc. (RTRX) CEO Eric Dube on Q2 2020 Results - Earnings Call Transcript
Retrophin (RTRX) delivered earnings and revenue surprises of 0.00% and -0.14%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Enrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now anticipated in 2021
Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, July 16, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2020 financial results on Thursday, July 30, 2020 after the close of...
Retrophin (RTRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the BMO 2020 Prescriptions for Suc...
SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a price ...
SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering, s...
Retrophin's (RTRX) CEO Eric Dube on Q1 2020 Results - Earnings Call Transcript
Retrophin (RTRX) delivered earnings and revenue surprises of 102.94% and 10.74%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dr. Bruhn brings more than 20 years of biopharmaceutical experience to the Retrophin Board Dr. Bruhn brings more than 20 years of biopharmaceutical experience to the Retrophin Board
Investors need to pay close attention to Retrophin (RTRX) stock based on the movements in the options market lately.
Topline data from 36-week proteinuria endpoint anticipated in first quarter of 2021 Topline data from 36-week proteinuria endpoint anticipated in first quarter of 2021
SAN DIEGO, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) will join the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORD...
Retrophin, Inc. (RTRX) CEO Eric Dube on Q4 2019 Results - Earnings Call Transcript
SAN DIEGO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for...
Here we discuss some biotech stocks, which are down this year so far but have the potential to bounce back next year.
Top Ranked Momentum Stocks to Buy for November 7th
About TVTX
There is no company description available.
| Industry Pharmaceutical Preparation Manufacturing | |
| Stock Exchange NASDAQ | Ticker Symbol TVTX |
Financial Performance
In 2019, TVTX's revenue was $175.34 million, an increase of 6.75% compared to the previous year's $164.25 million. Losses were -$146.43 million, 42.6% more than in 2018.
Analyst Forecasts
According to 8 analysts, the average rating for TVTX stock is "Strong Buy." The 12-month stock price forecast is 38.40, which is an increase of 25.65% from the latest price.